Antimicrobial resistance caused 4.95 million deaths associated with AMR and 1.27 million deaths attributable to AMR in 2019. Vaccines can prevent a proportion of the AMR burden by preventing drug-sensitive and drug-resistant infections, reducing antibiotic use and reducing pathogen transmission and chances of developing resistance genes. Increasing evidence from observational and modelling studies show the impact of vaccines on AMR.<\/p>\n\n\n\n
However, this evidence is yet to translate to policy and decision-making about which vaccines to develop, introduce so they effectively prevent AMR. This webinar will explore the mechanisms, evidence and value of vaccines in preventing AMR. A panel of experts will discuss what are the challenges to ensure that vaccines to prevent AMR are developed and widely used.<\/p>\n\n\n\n
Scientists, product developers, regulators, policy makers, implementers and funders interested in the role of vaccines in preventing AMR<\/p>\n\n\n\n
– The threat of AMR and ways through which vaccines can prevent it;
– Assessment of the value of vaccines in preventing AMR;
– Research priorities on vaccines and AMR;
– Development pipeline for vaccines against AMR priority pathogens;
– The role of vaccines in National Action Plans on AMR;
– Stories from the field: how vaccines were used in Zimbabwe to prevent AMR;
– Challenges and opportunities to ensure that vaccines against AMR are developed and used.<\/p>\n\n\n\n